Showing results (241-250 of 352) with videos related to
Sort By:
Pageof 36
Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.Journal of Drugs in Dermatology : JDD|February 6, 2025
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus PanelMilaan Shah, Joshua Burshtein, Danny Zakria, et al.The New England Journal of Medicine|November 25, 2003
A novel targeted T-cell modulator, efalizumab, for plaque psoriasisMark Lebwohl, Stephen K Tyring, Tiffani K Hamilton, et al.Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.Journal of Drugs in Dermatology : JDD|May 6, 2024
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)Todd Schlesinger, Leon Kircik, Mark Lebwohl, et al.Journal of Drugs in Dermatology : JDD|August 16, 2021
Advances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel ReportJames Del Rosso, April W Armstrong, Brian Berman, et al.The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.Pageof 36